. The prescribing information or tertiary sources did not mention use of estimated glomerular filtration rate (eGFR) or the Modification of Diet in Renal Disease Study (MDRD) equation. Epocrates Rx provided the most abbreviated renal dosing information, whereas AHFS Drug Information was the most comprehensive, and Lexi-Comp includes a renal function calculator. Nearly all (86%) clinical pharmacists indicated that automated eGFR is reported at their institutions, although they do not use these predictions for dosing in patients with impaired renal function, and their approaches to renal function estimation varied widely. Conclusion. Reporting of renal function methods and dosing recommendations for patients with impaired renal function requires standardization in order to ensure optimal dosing. Pharmacy clinicians do not substitute eGFR in place of creatinine clearance for renal dosing, which is consistent with current prescribing information. Studies are needed that will evaluate the validity of using eGFR to predict drug clearance and thereby generate dosage recommendations.
pharmacotherapy. This approach to patient care management is now a part of the core curriculum of most doctor of pharmacy education programs, and a broad array of secondary and tertiary reference sources are available for clinicians to use as the basis for the initiation of such a program in their institution and/or practice. One of the challenges of getting the "right" dosage regimen is accurately determining or, in most cases, estimating the individual patient's renal function. Many renal function estimation approaches have been proposed, and the Cockcroft-Gault equation, which provides an estimate of creatinine clearance (Cl cr ), has gained the most widespread acceptance. 1 Recently, several equations to estimate renal function as glomerular filtration rate (eGFR) have emerged from a secondary analysis of the Modification of Diet in Renal Disease (MDRD) study. 2 The availability of these methods has stimulated assessments of the accuracy of the various methods for estimation of renal function (eGFR vs Cl cr ) in a broad array of patient populations. The automated reporting of eGFR, calculated from the four-variable MDRD equation, is now routinely provided by many hospital laboratories whenever a serum creatinine value is measured, as a tool to enhance the iden-tification and classification of individuals with CKD. This initiative coupled with the introduction of a new calibrated creatinine assay has led to uncertainty among practitioners as to which method of renal function assessment should be used as the foundation for individualizing dosage regimens. 3, 4 Assessment of renal function in the clinical setting is most often accomplished by estimating Cl cr , which can be used as an index of the need for starting drug therapy at a reduced dosage or frequency or for altering a current dosage regimen; to determine a priori pharmacokinetic parameter estimates to facilitate the calculation of an individualized dosage regimen for drugs with a narrow therapeutic index; and to monitor renal function status in order to identify the early onset of nephrotoxicity. This is most important for drugs that are eliminated primarily by renal mechanisms or that are not monitored by using drug concentrations to guide dosing. For example, if the dofetilide dosage is not tailored for patients with CKD or AKI, their safety could be jeopardized since a strong relationship between elevated plasma concentrations and adverse outcomes has been noted, including QT-interval prolongation and ventricular arrhythmias. 5 In an effort to improve the standardization and quality of renal dosing information provided by drug manufacturers in their drug labeling for new molecular entities (NMEs), the United States Food and Drug Administration (FDA) published its "Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling" (referred to as the Guidance in this article) in 1998. 6 The impact of this Guidance on the clarity, consistency, and quality of the labeling regarding drug dosing recommendations was assessed very early after its implementation, but a rigorous assessment remains to be conducted. 7 Furthermore, whether the relationship between the NME's pharmacokinetic parameters and clinically relevant renal function parameters such as measured or estimated Cl cr or GFR has been adopted or incorporated into tertiary and Webbased reference sources has not been determined.
The objectives of this study were 3-fold: to characterize the renal function parameters used as foundational indexes to indicate the need for renal dosage adjustment provided in prescribing information for NMEs approved in the postGuidance era (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) , to tabulate the renal function parameters in four commonly used tertiary drug dosing references, and to evaluate the renal function quantification methods most commonly used by nephrology and critical care clinical pharmacists to develop individualized dosage regimens for patients with CKD or AKI. 
Methods

Prescribing information (package inserts) for all
Results
Drug dosing recommendations for patients with CKD or AKI were identified in the Clinical Table 1 ). The remaining 207 NMEs contained no specific renal dosing recommendations. For 8 of these 44 NMEs, an altered dosage regimen was proposed; however, no quantifiable index of renal function was reported in the renal dose recommendation label language, or the renal function terminology and quantitative categories were inconsistent with those suggested in the Guidance (Table 2 ).
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The most common measure of renal function reported as the index to guide dosage adjustment in the prescribing information was Cl cr (42 of 44 NMEs). The quantitative renal function characterizations of the descriptive categoric terminology information in the prescribing information was almost uniformly consistent with the definitions and ranges of renal function as recommended in the Guidance: mild (Cl cr 50-80 ml/min), moderate (Cl cr 30-50 ml/min), or severe (Cl cr < 30 ml/min) renal impairment. In four NMEs, the renal function terminology was dissimilar to that suggested in the Guidance (Table 2) . In six NMEs, a lack of adequate information on renal impairment resulted in recommendations to either avoid using the drug in patients with severe renal insufficiency (Cl cr < 30 ml/min) or an ambiguous recommendation was provided (Table 3) . 11, 17, [21] [22] [23] [24] 779 Cl cr = creatinine clearance.
Table 3. Examples of Ambivalent Dosing Information in Prescribing Information for Selected New Molecular Entities
Generic Name Renal Dosing Information in Prescribing Information Memantine 21 "Adequate information in renal impairment is not available…" "Renal impairment will likely have higher exposure…" "Dose reduction in patients with moderate renal impairment should be considered…" "Avoid in severe renal impairment." Ranolazine 22 "In patients with varying degrees of renal impairment, ranolazine plasma levels increased up to 50%. The PK of ranolazine has not been assessed in patients on dialysis." In dose administration section, no renal dose recommendation is given.
In the prescribing information for most NMEs, there was no indication if the clinician should use a measured or estimated Cl cr to guide the selection of drug dosage. The Cockcroft-Gault equation for estimation of Cl cr was specifically mentioned in the most current prescribing information of only 11 NMEs (Table 4) . 5, 21, [25] [26] [27] [28] [29] [30] [31] [32] [33] Specific recommendations regarding the patient weight value that should be used in the estimation of Cl cr were stated in the prescribing information of just five of these NMEs: actual body weight (three NMEs) and lean or ideal body weight (two NMEs). The use of new descriptors of renal function, such as CKD, eGFR, or MDRD, was not reported in the prescribing information of any NME, and the most commonly used units of measure for Cl cr were ml/min (34 of 39 NMEs) and ml/min/1.73 m 2 (5 of 39 NMEs). The Epocrates Rx drug monographs provided the most limited and abbreviated renal dosing information of the four tertiary reference sources. Fifteen deviations from prescribing information regarding renal function index of choice were noted, with the most common being the omission of units of renal function measurement. For example, the dosage recommendations for ertapenem and adefovir are given as "Cl cr < 30: 500 mg qd," and "Cl cr 30-49: give q48h," respectively. In all cases, details regarding Cl cr estimation or determination methods were omitted compared with the prescribing information ( Table 4 ). The Lexi-Comp resource did not state a specific method of estimating Cl cr for any NME; however, the individual drug monographs included a "calculations" section that was linked to an interactive Cl cr calculator. The calculator provided the user with an option to calculate Cl cr by using either the Cockcroft-Gault equation (input actual body weight, yields Cl cr in ml/min) or the Jelliffe equation 34 (no weight input variable, yields Cl cr in ml/min/1.73 m Tables 5 and 6 . The MDRD equation was used by nephrology pharmacy practitioners most frequently in patients with impaired renal function with a GFR less than 60 ml/min/1.73 m 2 , whereas most of the critical care pharmacy practitioners never used the MDRD equation. Both groups used the Cockcroft-Gault equation in more than 90% of the patients for whom they planned to modify a drug dosage regimen. A variety of different patient weight adjustments were reported to be used with the CockcroftGault equation when patients were overweight or obese; however, neither pharmacy group used the Salazar-Corcoran equation for overweight patients more than 10% of the time. The Cl cr was reported by both pharmacy groups to be determined by urine collection (measured Cl cr ) very infrequently, with 45% reporting never or at most one patient/year. Antibiotics were the predominant agents listed in the top drugs for which the pharmacists provided renal dosage adjustments in their practice sites, with ertapenem, voriconazole, and daptomycin being the only NMEs that ranked in the top 20 (Table 6 ).
Vancomycin and the aminoglycosides (gentamicin and tobramycin) were in the top five for both practitioner groups.
Discussion
Drug dosage modification based on degree of renal insufficiency has been a standard of practice in many acute and ambulatory care settings for over 3 decades. [35] [36] [37] [38] [39] [40] The goals of these programs are to maximize therapeutic outcomes, minimize drug toxicity, and reduce health care costs associated with drug administration, adverse events, and hospitalizations. The clarity of dosage adjustment recommendations provided in the prescribing information is especially important for drugs that undergo extensive renal elimination and those for which therapeutic drug monitoring is not routinely performed. In the clinical setting, the first critical step is to accurately quantify a patient's renal function by using a method that is consistent with the clinical pharmacokinetic trial data for that drug, which was submitted as part of that drug's FDA approval documentation.
The most common index of renal function reported by drug manufacturers in prescribing information for drug dosing in patients with impaired renal function was Cl cr . The CKD staging criteria, which are based on an MDRDcalculated GFR value, were not mentioned in the prescribing information of any of the 44 NMEs. However, the widespread availability of the automated eGFR value in acute care settings (reportedly used in > 85% of institutions represented in our pharmacist survey), as well as recent recommendations by the National Kidney Disease Education Program, 41 raises concern that once generated, this renal function estimate could be used beyond its intended purpose of categorizing patients into CKD risk categories. 2 Use of eGFR or other alternate approaches to quantify renal function that are dissimilar to the methods provided in the prescribing information could result in marked variation in the calculated dosage regimen. Recent studies have consistently reported that the four-variable MDRD-derived eGFR overestimates Cl cr by up to 40% compared with the Cockcroft-Gault equation in patients with a GFR less than 60 ml/min/1.73 m 2 and that the use of eGFR for drug dosing has resulted in up to 50% higher prescribed doses of digoxin, amantadine, and cephalosporins. [42] [43] [44] [45] An overestimation of renal function by 20% would lead to a 20% increase in dose, higher drug concentrations, and thereby an increased risk of adverse events and drug-related problems. Although the clinical and economic implications of these dosing errors are unknown, the consequences would be most significant for drugs with a narrow therapeutic index and for drugs requiring a priori estimation of pharmacokinetic parameters that have been traditionally based on Cl cr , including digoxin, aminoglycosides, and vancomycin. Based on these concerns, many experts in the field of pharmacotherapy have cautioned against using alternate methods of renal function assessment outside of those reported in the prescribing information. 3, 46, 47 Few studies have reported dose calculations based on eGFR that show agreement with dose calculations that used directly measured GFR. For example, eGFR was reportedly more accurate than Cl cr for calculating the carboplatin dose when compared with measured GFR. 48 These findings are not surprising since eGFR equations are derived from iothalamate-measured GFR. A recent study reported that renal dosage adjustments based on eGFR values provided similar doses for selected drugs when compared with the Includes a new molecular entity identified in the prescribing information review.
Cockcroft-Gault equation. 49 However, it is important to note that the renal function index used to calculate the "gold standard drug dose" against which both the eGFR and CockcroftGault Cl cr groups were compared was measured GFR. Measured GFR is not mentioned in the FDA Guidance recommendations, was not used in the drug manufacturer pharmacokinetic studies in patients with impaired renal function in the 44 NMEs we reviewed, and is rarely available to practicing clinicians. In addition, the approach used by these researchers to determine drug dosage based on eGFR involved correction based on body surface area (BSA) to yield units in ml/minute instead of ml/minute/1.73 m 2 ; this approach has not been previously used in CKD staging, nor is it the value so frequently reported by clinical laboratories.
Another concern with automated eGFR reporting is that many clinicians are unaware of the version of the MDRD equation or the isotope dilution mass spectrometry creatinine assay calibration method that is used at their institution. It is also apparent that physicians find it difficult to interpret the automated eGFR in the clinical setting and its role in patient care. 50 We have shown that the use of eGFR for the development of renal dosing information of NMEs is currently rare, and further research may ultimately suggest that it is superior to Cl cr in predicting total drug clearance. Until data are available that fully characterize the relationship between renal dosage adjustment approaches and therapeutic outcomes, particularly for those drugs that do not undergo traditional therapeutic drug monitoring, this approach cannot be recommended. The common availability of eGFR suggests that its use in drug development and clinical practice must be evaluated.
The lack of clarity regarding the renal function index of choice for the renal drug dosage adjustment recommendations in the two tertiary resources that are most readily available to practicing clinicians and students is disconcerting. Approximately 250,000 physicians and 40,000 pharmacists are actively using Epocrates Rx software on mobile communication devices (personal communication, Erica Morgenstern, November 30, 2009) . A recent survey revealed that medical students are 4 times more likely to consult a mobile reference for a clinical question than to ask their attending physician. 51 This could be due to intimidation or simply the inability to find someone to ask. Unfortunately, nearly 90% of students surveyed view the information available through mobile or online drug and disease references, such as Epocrates Rx, as highly credible, second only to medical journals. The availability and convenience, however, should not imply quality and may in fact (based on our data and that previously reported 52 ) suggest a need for standardization of "trusted" resources.
The Cl cr is the gold standard renal function index reported in prescribing information. The specific details regarding use of measured versus estimated Cl cr is, however, rarely specified in the prescribing information, nor is the method for estimation reported. This may lead to potential errors in interpretation of renal dosage adjustments by health care providers. Methods used by clinicians that differ from the approaches used to create dosing guidelines for patients with impaired renal function increase the risk that a less than optimal dosage regimen might be implemented. Weight-based modifications of the Cockcroft-Gault equation are commonly reported in the literature. 53, 54 They are often used in clinical settings for overweight patients even though these approaches are not clearly specified in the prescribing information or in the pharmacokinetic studies of NMEs in patients with impaired renal function. This is likely because during drug development, obese individuals are most often excluded from pharmacokinetic studies or studies in patients with impaired renal function.
The results of our pharmacist survey indicate that most pharmacists use the Cockcroft-Gault equation to estimate renal function for renal drug dosage adjustments, and they apply a weight adjustment of the Cockcroft-Gault equation for overweight patients. The prescribing information for only a few NMEs recommend using a weightbased adjustment for the Cockcroft-Gault equation. Rigorous evaluation of these approaches is lacking, and the relationship between Cl cr calculated by these approaches and either drug pharmacokinetic parameters or drug therapy outcomes is yet to be defined. The availability of renal function calculators in tertiary sources such as Lexi-Comp may minimize calculation errors. However, the user is still required to make a choice between the Cockcroft-Gault equation (using actual body weight only) and the Jelliffe equation (no body weight required), which introduces additional variation in the renal function estimate. Because dosing guidelines for patients with impaired renal function in the prescribing information do not clearly provide guidance on this issue, there could be marked interclinician variation in a given patient' s drug dosage regimen.
The units of measure reported for Cl cr estimations in tertiary reference sources were often omitted and the recommended patient weight used to estimate Cl cr was often not described, leading to controversy among practitioners. We identified five NMEs for which the prescribing information indicated that a BSA correction would have to be applied to the CockcroftGault-estimated Cl cr values to yield results in the desired units of measure of ml/minute/1.73 m 2 ( Table 2 ). Another problem with the BSAcorrected approach is that there is no universally agreed-upon method to calculate it among investigators or regulators. Because of this, including BSA in renal drug dosing is likely to introduce a magnitude of variability in dosage calculations and recommendations. Since BSA is not often calculated in clinical settings, the best practice would be for drug manufacturers to avoid reporting Cl cr by using this unit of measure.
When dosing recommendations are provided for patients with impaired renal function, they are often based on one or more small, underpowered, unpublished pharmacokinetic studies that may only be referenced in review articles as "data on file" or not available at all. This can lead to ambiguous or problematic dosage regimen recommendations for patients with severe renal insufficiency, such as "insufficient data available" to make a dosing recommendation, as noted in about 10% of the NMEs (Table 3 ). Other noted shortcomings of renal drug dosing studies include lack of representative populations that would be treated with the drug (i.e., populations based on obesity, age, sex, race-ethnicity), incomplete understanding of which pharmacokinetic parameters (e.g., area under the concentration-time curve, average steady-state concentration, maximum concentration, minimum concentration) are important to match for renally impaired patients compared with those with normal renal function, and lack of pharmacodynamic outcomes to ensure adequate response and avoidance of adverse effects when renal drug dosing recommendations are applied. Publication of pharmacokinetic studies and studies in patients with impaired renal function and availability of the raw pharmacokinetic data in the public domain can provide further information about critical study methods, including the method of estimating renal function. For example, the prescribing information often suggests a renal dosage adjustment based on Cl cr , whereas the pharmacokinetic studies or studies in patients with impaired renal function might report that patients were stratified in the trial based on estimated Cl cr by using the Cockcroft-Gault equation with no weight index specified (e.g., telbivudine) or based on a 24-hour urine collection (solifenacin). 55, 56 In such cases, the practitioner has to make a clinical judgment regarding which Cl cr estimation method they will use for dosage adjustment purposes; this most often leads to use of some form of the CockcroftGault equation and involves a weight-based Cockcroft-Gault equation. Having these critical aspects of the pharmacokinetic studies and studies in patients with impaired renal function included in the medical or clinical pharmacology reviews that are available on the FDA Center for Drug Evaluation and Research (CDER) Web site or provided as active Web links within the Webresiding prescribing information would be helpful. A best practice would be to conduct pharmacokinetic studies and studies in patients with impaired renal function by using Cl cr from an accurately timed 24-hour Cl cr or CockcroftGault equation with a specified weight index to stratify patients into renal function categories, with poststudy analysis of the relationship between the critical pharmacokinetic parameters and variants of the Cockcroft-Gault and eGFR equations. This approach would provide maximum transparency and avoid major assumptions associated with renal function estimation methods. Appendix 1 provides a list of our best practice recommendations.
The prescribing information provided to clinical practitioners is the result of a negotiation between the FDA and the drug sponsor. The FDA CDER review teams are composed of physicians, clinical pharmacologists, biostatisticians, and others, who make recommendations for drug labeling. The February 2009 draft guidance on labeling for human prescription drugs and biologics 57 identifies where renal dosing guidelines should be provided but does not provide the detail to the extent that we suggest. The FDA's 2008 preliminary concept paper 58 updates the 1998 document 6 but has made very few changes in the recommended labeling section. As the concept paper receives comments and evolves into an official guidance, an investigation such as presented here should help to inform the process.
Conclusion
Reporting of renal function estimation methods and dosing recommendations for patients with impaired renal function would benefit from standardization not only in the study conduction process but also the language of the labeling that appears in official prescribing information and secondary and tertiary sources. This would enhance the potential for optimal dosing of drugs that are excreted primarily unchanged by the kidneys. Substitution of alternate methods of renal function estimation, such as eGFR, in place of Cl cr , for renal dosing is not supported by the results of this study, which revealed that in the clinical setting and drug development arenas Cl cr is by far considered the renal function index of choice. Widespread adoption of eGFR for renal dosing will require either new studies for each drug or a secondary analysis of the original data from the previous investigations conducted of these NMEs.
